Nyanda Elias Ntinginya

Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages

David Stucki, Daniela Brites, Leïla Jeljeli et al. · Nature Genetics · 2016 · 465 citations · Full text

Pulmonary Tuberculosis, Tuberculosis Prevention, Tuberculosis +2

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

Martin J. Boeree, Norbert Heinrich, Rob E. Aarnoutse et al. · The Lancet Infectious Diseases · 2016 · 379 citations · Full text

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt et al. · The Lancet · 2015 · 248 citations

Pulmonary Tuberculosis, Phase 2B, Tuberculosis Prevention +9

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

Conor Tweed, Rodney Dawson, Divan A. Burger et al. · The Lancet Respiratory Medicine · 2019 · 143 citations · Full text

Assessment of the novel T-cell activation marker–tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study

Damien Portevin, Félicien Moukambi, Petra Clowes et al. · The Lancet Infectious Diseases · 2014 · 136 citations

Pulmonary Tuberculosis, Allergy, Immunodeficiencies +8